1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market

First Data Cut Shows 83% Efficacy Against Infection

 
• By Andrew McConaghie

Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.

Moderna logo
• Source: Shutterstock

Moderna has unveiled strong topline results from its Phase III study of its respiratory syncytial virus (RSV) mRNA-based vaccine in older people, which suggests it could mount a challenge to frontrunners from GSK and Pfizer.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 
• By Jessica Merrill

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

Profile: Anil Koul’s Journey From ‘Jumping Genes’ To Sirturo And AI-Led Drug Discovery

 
• By Anju Ghangurde

Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.

Merck’s HIV Combo Shows Non-Inferiority To Gilead’s Biktarvy

 
• By Alaric DeArment

The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.

Gilead Pushes PrEP Envelope As ViiV Explores Self-Administered, Long-Acting Drugs

 
• By Alaric DeArment

The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.

More from Therapy Areas

Vocal For ‘Glocal’: How Menarini Is Adapting To Outperform In The Asia Pacific

 
• By Anju Ghangurde

Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.

Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success

 
• By Alaric DeArment

The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 
• By Andrew McConaghie

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.